Status:
TERMINATED
A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration
Lead Sponsor:
Allergan
Conditions:
Choroid Neovascularization
Age-Related Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
This is a 24-month study to evaluate multiple doses of AGN211745 (previously known as Sirna-027) in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration
Eligibility Criteria
Inclusion
- 50 years or older with "wet" AMD as determined by an ophthalmologist
- decrease in visual acuity (20/40 to 20/640) in at least one eye
Exclusion
- Uncontrolled systemic disease
- History of heart attack or stroke within one year of study entry
- Symptomatic coronary artery disease
- Cataracts that interfere with vision
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT00395057
Start Date
January 1 2007
End Date
February 1 2009
Last Update
September 7 2015
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Houston, Texas, United States
2
Sydney, New South Wales, Australia
3
Makati, Philippines